Fig. 3: T cell response in patients with cancer. | Nature Cancer

Fig. 3: T cell response in patients with cancer.

From: Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Fig. 3: T cell response in patients with cancer.

a,b, Representative plots of CD4+CD137+OX40+ (CD4+) and CD8+CD137+CD69+ (CD8+) T cells in a patient with confirmed COVID-19 and a cancer patient without COVID-19 after in vitro stimulation with S, M and N peptide pools, positive control Staphylococcal enterotoxin B (SEB) or negative control (NC). c,d, Frequency of SARS-CoV-2-specific CD4+ (c) and CD8+ (d) T cells in patients with solid malignancies (n = 83). e,f, Frequency of SARS-CoV-2-specific CD4+ (e) and CD8+ (f) T cells in patients with hematological malignancies (n = 21). The stimulation index was calculated by dividing the percentage of positive cells in the stimulated sample by the percentage of positive cells in NC. To obtain the total number of SsT cells, the sum of cells activated by S, M and N was calculated (SMN). Boxes indicate the 25th and 75th percentiles, the line indicates the median and whiskers indicate 1.5 × IQR. Dots represent individual samples. Dotted lines and gray boxes denote the limit of detection.

Source data

Back to article page